October 15, 2019 -- InvestorsHub NewsWire -- via
BioResearch Alert's Blog
- About: Puration, Inc.
(PURA), Includes: ACB, CGC, NOUV
Originally Published on SeekingAlpha.com/PURA
- Canada 2.0 CBD legalization goes into effect October 17,
2019
- Of 650 Chefs surveyed at the
American Culinary Federation, 75% said cannabis infused foods will
be the hottest trend starting in 2019 and beverages are at the top
of the list.
- PURA has big head start in CBD infused beverages and offers CBD
Sports Water, CBD Tea, and now CBD Coffee.
- Coca Cola’s interest in CBD infused
Coca Cola confirms PURA CBD beverage growth targets.
- PURA Reports 87% Revenue
Growth Breaking $1 Million In First 6 Months Of 2019 from Cannabis
Infused beverages and confirms $4 million 2019 sales target.
- Goldman reports $0.35 PURA
Target in New Analyst Research Report
Puration, Inc. (PURA) today announced an
anticipated sales boost from Cannabis 2.0 – the legalization of
cannabis infused edibles and beverages in Canada going into effect
later this week on October 17th. PURA management has
observed a movement in Canada toward CBD infused sports nutrition
beverages. Both Aurora Cannabis (OTC:ACB) and Canopy Growth
(OTC:CGC) have made recent
moves into the sports nutrition beverage sector. Aurora has entered
into a deal with the UFC and Canopy acquired sports beverage maker
BioSteel Sports Nutrition. PURA management has recently reported
Canadian inquiries regarding various contractual opportunities with
PURA’s leading sports nutrition beverage EVERx
CBD Sport Water. While other companies are looking to get
into the $50 billion sports nutrition sector, PURA has over two
years of experience producing and selling its EVERx product.
Multiple surveys indicate consumers are eager to purchase
edibles and beverages. Specifically, a study conducted by research
firm Deloitte reported that
over half of surveyed respondents were likely to try
cannabis-edibles, and 37% were likely to try
cannabis-beverages. PURA commissioned its own survey
on the cannabis beverage sector that is available for review
online.
In addition to the inquiries from Canada about PURA’s EVERx
reported by management, PURA has a ready partner of its own as an
entry into the Canada 2.0 market opportunity. The CEO of PURA,
Brian Shibley, is also the CEO of PURA spinoff, Nouveau (OTCPK:NOUV) a cannabis
cultivator with a licensed operation in Canada. NOUV’s Canadian
operation is small today, but still gives PURA access to Canada 2.0
while evaluating other suitors that may give PURA accelerated
access to the Canada 2.0 market.
PURA has reported over $1 million in CBD beverage sales in the
first six months of 2019 after reporting approximately $1 million
in sales for all of 2018. On top of its ongoing sales, PURA has
signed a new European distribution agreement
anticipated to generate $4 million annually with a first
shipment scheduled later this month. PURA has also recently
announced a new distribution agreement in Latin
America. PURA offers CBD Sports Water, CBD Tea, and recently
announced a new line of CBD coffee.
Goldman Small Cap Research CBD beverage industry was conducted
in conjunction with the PURA's initiative to launch new CBD Infused
beer, coffee and tea beverages. Goldman summarizes the results with
a confirmation of the $0.35 Price target for the shares of PURA and
a Speculative Buy recommendation issued on September 25, 2019 (see
link below to Sep 25 Analyst Report).
"Great Entry Point for Emerging Leader. With the stock basing at
current levels, even a modest series of news and milestone events
should drive the stock toward our price target. Moreover, with
strong seasonality in the current quarter, and new markets just
opened, PURA has the wind at its back."
"Key Numbers: When asked in order of preference what CBD-infused
beverage they would buy, 77 or 31% said tea and 74 or 30% said
water. As a provider of water and tea, PURA leadership certainly is
providing consumers the most popular categories of CBD-infused
beverages which bodes very well for future sales and market share
growth."
"The Trend is PURA's Friend: While CBD oils remain the most
popular source of CBD products, the data and responses indicate
that oils, vapes, and tinctures usage may be swapped on an
ever-increasing scale, for edibles and beverages. We expect that
they will eventually overtake these product categories which will
be a boon to PURA."
"Conclusion: While the interim CBD user survey results were
favorable for PURA, the final results were overwhelmingly positive
for the Company's future. There are a number of surprising results
from this survey, which had a final identifiable respondent tally
of 246 participants, as compared with our 85 identifiable responses
when we issued interim results. The bottom line is that these
results affirm to us that PURA is well-positioned to lead the
CBD-infused beverage market and we reiterate our $0.35 price
target."
Tomorrow, On Friday, October 11, 2019, PURA will publish an
update on the launch of TranquiliTeaCBD and a new coffee infused with CBD
in addition to including a progress update on the company's
progress toward its 2019 $4 millionsales milestone.
PURA has reported over $1 million in CBD beverage sales in the
first six months of 2019 after reporting approximately $1 million
in sales for all of 2018. On top of its ongoing sales, PURA has
signed a new European distribution agreement
anticipated to generate $4 million annually with a first
shipment scheduled later this month.
To see the full final CBD Beverage industry survey results,
follow the link below:
CBD Beverage Industry Results – October
10, 2019
To see the original full Analyst Report, follow the link
below:
PURAITON, Inc. Research Analyst
Report – September 25, 2019
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur. These statements have not been evaluated
by the Food and Drug Administration. These products are not
intended to diagnose, treat, cure, or prevent any disease.
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
